- In February 2024, Abreva launched an innovative campaign to empower individuals affected by cold sores by unveiling a unique, diamond-studded lip design. This initiative aims to challenge the stigma associated with cold sores and promote self-acceptance. Research indicates that two-thirds of young individuals with cold sores experience a decline in self-esteem and confidence during outbreaks, highlighting the importance of awareness and support
- In December 2022, BioNTech commenced a Phase 1 clinical trial for BNT163, an mRNA vaccine designed to prevent genital lesions caused by HSV-2 and potentially HSV-1. The trial aims to evaluate the vaccine’s safety, tolerability, and efficacy in eliciting an immune response. BNT163 specifically targets three HSV-2 glycoproteins to inhibit viral entry and transmission while mitigating its immunosuppressive effects
- In July 2021, Devirex introduced Lipivir, marking a significant transition from laboratory development to market distribution. The Lipivir lip gel, formulated to prevent cold sores, became available in pharmacies, drugstores, beauty spas, and online platforms across Switzerland and Austria in early 2021. This launch followed extensive research, development, and rigorous testing to ensure efficacy and consumer safety
- In November 2020, Amneal Pharmaceuticals, Inc. announced that the FDA had approved its Abbreviated New Drug Application (ANDA) for Acyclovir Cream, 5%. This generic equivalent of Zovirax is indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents aged 12 and older. Available by prescription, the cream may cause mild side effects, including nausea
Frequently Asked Questions
GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sun Pharmaceutical Industries Ltd. (India), are the major companies in the central fill pharmacy automation market.
In July 2021, Devirex introduced Lipivir, marking a significant transition from laboratory development to market distribution. In November 2020, Amneal Pharmaceuticals, Inc. announced that the FDA had approved its Abbreviated New Drug Application (ANDA) for Acyclovir Cream, 5%.
The countries covered in the ophthalmic operational microscope market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, and rest of Middle East and Africa
